Funding Wizard

The National Institutes of Health (NIH) Office of Nutrition Research (ONR) and participating NIH Institutes and Centers (ICs) intend to publish a Funding Opportunity Announcement (FOA) for new applications that will support new institutional research training programs (predoctoral, postdoctoral or both) in artificial intelligence (AI) for precision nutrition (AIPrN) that will focus on integration of the domains of precision nutrition, AI including machine learning (ML), systems biology, systems science, Big Data, and computational analytics. The goal is to build a future workforce that will be able to use growing data resources to tackle complex biomedical challenges in nutrition science that are beyond human intuition. It is hoped such research will lead to the development of innovative solutions to combat diet-related chronic diseases within the mission areas of the participating ICs. The vision of the AIPrN training program is to support the development of a diverse research workforce capable who will possess advanced competencies in AI including machine learning and data science analytics to apply to an increasingly complex landscape of Big Data from the molecular, to organismal, to community and societal scales related to nutrition and diet related conditions.

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NCI R25 program is to support research and educational activities that enhance the diversity of the cancer biomedical workforce. We seek to do this by providing training navigation to support scholars from diverse backgrounds, including individuals from groups shown to be underrepresented in the cancer biomedical workforce. The TEAM program will pilot test the use of training champions (TCs) at minority serving institutions (MSIs) to support the development of educational activities and scientific career development programs to enhance the preparation, productivity and progress of scholars from diverse backgrounds, including those from underrepresented racial and ethnic groups, in the Notice of NIH's Interest in Diversity, NOT-OD-20-031. The career development levels of focus for this FOA will include predoctoral and postdoctoral fellows, and early-stage investigators (ESIs). TCs are defined as personnel located within the MSI who can assist potential applicants with their plans to apply, attain, or transition to an independent grant award. This RFA will leverage TCs to assist scholars in identifying funding opportunities, networking with appropriate NCI/NIH program directors, and locating resources for competitive application preparation. TCs will also provide additional training support, navigation, and resources to enhance the skills required to successfully identify, prepare, submit, and obtain grants and career development opportunities. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development and Mentoring Activities.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U01 research projects. The applicants should propose to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities.As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.

The purpose of the NIH HEAL InitiativeSM Pathway to Independence Award (K99/R00) program is to enhance workforce diversity in the research workforce and maintain a strong cohort of new and talented independent investigators conducting Pain and/or SUD research, in order to increase the pool of diverse and independent investigator workforce in research areas supported by the NIH HEAL InitiativeSM. This program is designed to facilitate a timely transition of eligible postdoctoral researchers from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition to help awardees establish independent research programs in areas supported by the NIH HEAL InitiativeSM. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, an ancillary clinical trial, or an independent Basic Experimental Studies with Humans (BESH). Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (RFA-NS-22-025).

The purpose of this funding opportunity announcement (FOA) is to establish Centers to support research that will accelerate the translational use of Microphysiological Systems (MPS) in drug development through regulatory acceptance and adoption for industrial use, by establishing MPS that are fit-for-purpose for industry needs and have specific defined contexts of use (CoUs) and will be developed with consideration of applicable expectations to achieve regulatory approval. For this FOA, the term drugs refers to both human pharmacological and biological products unless otherwise specified. These Centers will further the development of MPS as drug development tools (DDTs) that, once qualified, will be made publicly and commercially available to fill unmet needs in drug development.

The purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery of strong candidate biomarkers or biomarker signatures for pain that can be used to facilitate the testing of non-opioid pain therapeutics in Phase II clinical trials.The biomarkers or biomarker signature will be developed through clinical research specifically focused on the identification of pain biomarkers or biosignatures that predict and/or monitor response to pain therapeutics. The resulting biomarkers or biomarker signatures may be focused on a single pain condition or on several pain conditions with common underlying pathophysiology. Applications to identify biomarkers or biomarker signatures that predict or monitor a therapeutic response across several related pain conditions should feature Multiple Principal Investigator (MPI)-led teams that represent each of the related pain conditions and associated clinical networks. The MPI-led teams are expected to decide upon a single set of measures or biomarker modalities (i.e., combination of omics, QST, actigraphy, EEG, digital measures, etc.) as components of the biosignature for all pain conditions represented in the application. Applications should feature centralized resource groups that will coordinate clinical trials and standardize all sample or data collection methods, technology development, statistical analysis and algorithm development across the pain conditions under investigation. Applications seeking to develop biomarkers or biomarker signatures that will be used to predict and/or monitor a therapeutic response for a single pain condition must also feature MPI-led teams that represent the cross functional expertise necessary for biomarker and/or signature development, along with the same types of centralized resource groups that coordinate clinical trials and standardize sample or data collection methods, technology development and statistical analysis.

Avenir means future in French, and the Avenir Award Program for Research on Substance Abuse and HIV/AIDS looks toward the future by supporting early stage investigators (ESI) proposing highly innovative studies that address NIH HIV/AIDS Research Priorities https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-137.html. The Avenir Award Program for Research on Substance Abuse and HIV/AIDS will support creative individuals who wish to pursue innovative research at the nexus of substance abuse and HIV/AIDS. The nexus with drug abuse should be clearly described. The Avenir Award Program for Research on Substance Abuse and HIV/AIDS will support research approaches, both basic and clinical, which have the potential to benefit substance using populations with or at risk for HIV/AIDS by reducing HIV incidence, improving therapies for HIV, reducing the impact of comorbid conditions, and ultimately, eradicating HIV.

This Funding Opportunity Announcement (FOA) invites grant applications for the Research Specialist Award (R50) in any area of NCI-funded cancer research. This FOA is specifically for laboratory-based scientists.The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical, or population science cancer research program, but not serve as independent investigators. These non-tenure track scientists, such as researchers within a research program, are vital to sustaining the biomedical research enterprise. It is anticipated that only exceptional scientists who want to pursue research within the context of an existing NCI-funded cancer research program, but not serve as independent investigators, will be competitive for this award.

Emergency Award: This Funding Opportunity Announcement (FOA) solicits research applications that propose implementation science methodology to embed existing evidence-based coordinated pain care models into a variety of public and private health care systems (HCS) where this type of care does not exist. Applications that combine comparative effectiveness studies of innovative coordinated care models with strong implementation science methodology to embed effective approaches into HCSs also are encouraged. This FOA requires that the coordinated care model under study be embedded into the health care delivery system of the applicant institutions. Coordinated pain care approaches proposed for study should include interventions from multiple disciplines as described below and should aim to improve pain management based on the biopsychosocial model of pain. Emphasis should be on populations of patients with greatest need. This FOA solicits applications from HCS who have resources and infrastructure to support research and implementation of study approaches in partnership with those HCS who lack research resources or experience and would benefit most from implementation of cost-effective coordinated pain care. HCS partners who serve populations that are under-represented in research are encouraged to apply. Models of coordinated care proposed by the study team should be aligned with health care resources of the participating HCS and should be informed through engagement of stakeholders including patients, providers, healthcare system executives, policy makers, and payors. The study teams must include health care providers from multiple disciplines and implementation scientists.

The purpose of this FOA is to invite applications for a Coordinating Center for the Environmental influences on Child Health Outcomes (ECHO) program. The ECHO Cohort Coordinating Center will provide comprehensive operational leadership and an organizational infrastructure to manage and coordinate all ECHO Cohort activities. The Coordinating Centers main roles are to: 1) Provide oversight and effective project management for all aspects of the ECHO Cohort consortium; 2) Support multiple ECHO Cohort committees and serve as the centralized ECHO Cohort communications center; and 3) Administer the Opportunities and Innovation Fund. This FOA runs in parallel with companion FOAs that solicit applications for Cohort Study Sites for follow-up of existing ECHO Cohort participants and for recruitment of new pregnant participants (RFA XXXX), for Cohort Study Sites only for follow-up of existing ECHO Cohort participants (RFA XXXX), for Cohort Study Sites only for recruitment of new pregnant participants (RFA XXXX), for an ECHO Data Analysis Center (RFA XXXX), for an ECHO Measurement Core (RFA XXXX), and for an ECHO Laboratory Core (RFA XXXX).